Skip to main content
Fig. 3 | Malaria Journal

Fig. 3

From: Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission

Fig. 3

The expression profile and localization of Pb51. a Western blot analysis of Pb51 expression in lysates from P. berghei schizont (S), gametocytes (G), and ookinetes (O). Anti-HSP70 serum was used for protein loading control. b IFA analysis of Pb51 localization. Different stages (rings, schizonts, gametocytes, zygotes, retorts, ookinetes and sporozoites) at different time points of P. berghei development were used. Pb51 was detected by FITC-conjugated secondary antibodies (green). Cells were permeabilized with 0.1% Triton X-100. Pbs21 mAb was used for surface staining of ookinetes. BF bright field. c Co-localization IFA analysis of Pb51 expression. Retorts and ookinetes were proceeded directly for antibody binding. Anti-rPb51 rabbit sera was used as first antibodies and detected by Alexa Fluor 555-conjugated secondary antibodies (red). Anti-Pbs21 mouse mAb was used for surface staining detected by FITC-labeled secondary antibodies (green). For Fig. 3b, c, parasite nuclei were stained with DAPI (blue). The scale bar indicates 5 µm

Back to article page